-
DarioHealth launches strategic review after unsolicited inquiries
-
DarioHealth Corp. (DRIO) PT Lowered to $1.25 at Stifel
-
DarioHealth (DRIO) Tops Q2 EPS by 38c
-
DarioHealth (DRIO) and GreenKey partner to target sleep apnea market
-
DarioHealth (DRIO) Files for 52.14M Share Offering by Selling Stockholders
-
Litchfield Hills Research Starts DarioHealth Corp. (DRIO) at Buy
-
DarioHealth Corp. (DRIO) PT Lowered to $1.50 at Stifel
-
DarioHealth (DRIO) Tops Q1 EPS by 24c
-
DarioHealth (DRIO) announces retirement of CFO Ben-David, new CFO Franco-Yehuda
-
DarioHealth (DRIO) partners with leading benefit administrator to offer cardiometabolic solution
-
DarioHealth Corp. (DRIO) PT Lowered to $2 at Stifel
-
DarioHealth (DRIO) Reports Q4 results
-
DarioHealth (DRIO) Signs First Healthcare System as Employer Contract
-
DarioHealth (DRIO) Appoints Larry Leisure to its Board
-
DarioHealth (DRIO) secures new agreement with Blue Cross Blue Shield
-
TD Cowen Downgrades DarioHealth Corp. (DRIO) to Hold
-
DarioHealth (DRIO) Signs Four New Employer Contracts Across Full Product Suite
-
DarioHealth (DRIO) Tops Q3 EPS by 47c
-
DarioHealth (DRIO) Tops Q2 EPS by 53c
-
DarioHealth (DRIO) Expands GLP-1 Solution Client Base with New Employer Contract
-
TD Cowen Reiterates Buy Rating on DarioHealth Corp. (DRIO)

